Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2009

Cellectis to Employ Diatos’ Drug Delivery Platform

  • Cellectis acquired the Vectocell® intracellular delivery technology from Diatos to optimize the efficacy of its drug candidates. This platform reportedly improves the performance of a therapeutic compound by enabling specific entry into the target cell compartment or organ in animals and humans.

    It is based on the fusion between the therapeutic protein and an antibody-derived peptide that facilitates passive entry into the cell. Experimental data shows that this targeting technique provokes minimal immunogenicity and thus reportedly offers excellent safety.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »